article thumbnail

Lung cancer deaths decline but.

World of DTC Marketing

In recent years, early detection and treatment improvements have helped boost the 3-year survival rate for lung cancer from 21% in 2004 to 31% in 2015 through 2017. But it’s still the leading cause of cancer deaths. Although lung cancer’s mortality rate has fallen, the disease is still the leading cause of cancer deaths.

Insurance 271
article thumbnail

European Commission revokes marketing authorisation for Novartis’ crizanlizumab

European Pharmaceutical Review

Novartis said the decision to revoke the authorisation was based on a review of crizanlizumab under Article 20 of Regulation (EC) No 726/2004. EMA required the STAND study as part of the marketing authorisation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New Bill could enhance UK clinical trial regulation

European Pharmaceutical Review

If achieved, this would boost the UK’s competitiveness as a leading international site for trials. This activity should bring together relevant data sets which are collected by both the Medicines and Healthcare products Regulatory Agency (MHRA) and HRA. Mansfield also listed the main elements of The Future Clinical Trials Bill.

Ethics 83
article thumbnail

The EU HTA regulation: a new frontier for access to innovative technologies

European Pharmaceutical Review

border healthcare, specifically by repealing Article 15, which originally laid down the modalities and principles for co-operation between Member States in assessing new health technologies. governmental healthcare organisations. Vincenzo Salvatore is of counsel and leader of the Healthcare and Life Sciences Focus Team at BonelliErede.

article thumbnail

Interchangeability of biosimilars in the EU – the industry impact

European Pharmaceutical Review

1 However, as most biosimilars are developed by means of a complex biotechnological process in living organisms, this inevitably leads to differences between the biosimilar and the reference product. Marie Manley leads Sidley’s Life Sciences team in London and is a distinguished thought leader and adviser on EU and UK regulatory law.

article thumbnail

Industry Briefs April 2023

PM360

The Lupus ABC will, for the first time, truly give people who live with lupus and their caregivers a platform where they can be heard and involved in the treatment development process directly with all stakeholders,” said Veronica Vargas Lupo, co-lead of the Consortium’s Lupus Voices Council. “As

article thumbnail

How can the pharma industry address the gap in talent recruitment and development?

pharmaphorum

For instance, in pharmaceutical manufacturing, mistakes in training can lead to contamination or waste, which can cause businesses unnecessary headaches. When it comes to recruitment, the pharmaceutical industry should be well placed to capitalise on a society that now has healthcare front of mind. Raising the profile.